CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a
webcast and conference call on Wednesday, February 27, 2019 at 5:00 p.m.
EST to discuss its fourth quarter and full year 2018 operating and
The webcast will be accessible under “Events & Presentations” in the
Investors/Media page of the company’s website at www.acceleronpharma.com.
Individuals can participate in the conference call by dialing
877-312-5848 (domestic) or 253-237-1155 (international) and refer to the
“Acceleron Fourth Quarter and Full Year 2018 Earnings Call.”
The archived webcast will be available for replay on the Acceleron
website approximately two hours after the event.
Acceleron is a clinical-stage biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to treat
serious and rare diseases. The Company’s leadership in the understanding
of TGF-beta biology and protein engineering generates innovative
compounds that engage the body’s ability to regulate cellular growth and
Acceleron focuses its research and development efforts in hematologic,
neuromuscular, and pulmonary diseases. In hematology, the Company and
its global collaboration partner, Celgene, are developing luspatercept
for the treatment of chronic anemia in myelodysplastic syndromes,
beta-thalassemia, and myelofibrosis. Acceleron is also advancing its
neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and
ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary
Acceleron Pharma Inc.
Todd James, IRC, (617)
Vice President, Investor Relations and Corporate
Matt Fearer, (617) 301-9557